Study of QLH12016 plus a hormonal therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called QLH12016 combined with a hormonal therapy for men with advanced prostate cancer that has spread. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have prostate cancer that has spread to other parts of the body.
- You need to have recovered from side effects of previous cancer treatments.
- You cannot have taken certain experimental drugs or other cancer treatments within the past few weeks.
- You must not have cancer that has spread to the brain or spinal cord.
- You need to be able to swallow pills and not have severe stomach or intestine problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug, QLG1080, for patients with advanced prostate cancer that still responds to hormone therapy. It aims to see if the drug is safe and effective when combined with standard hormone treatment.
This early-stage trial tests a new drug (QLF4113) designed to help the immune system fight metastatic castration-resistant prostate cancer—a type that has spread and stopped responding to standard hormone therapy. You may qualify if you've already tried other treatments and your overall health is stable enough for the study.
This trial tests QLC5508, a new targeted drug for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The drug is designed to work in patients whose cancer has progressed despite prior hormone-based treatments.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.